ArticleFrontiers in bioengineering and biotechnology2026
Upstream process optimization and its critical role in chimpanzee adenoviral vector clinical drug development: lessons learned from VRON-0200 manufacturing.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimpanzee adenoviral (AdC) vectors represent a powerful platform for immunotherapies due to their strong immunogenicity, excellent safety profile, low human seroprevalence, and minimal cross-neutralization to prevalent human serotypes. Despite these advantages, AdC manufacturing presents unique challenges, including elevated infectivity ratios, transgene-dependent replication kinetics, and higher impurity burdens compared to well-characterized human adenovirus systems. During VRON-0200 development, a first-in-class heterologous AdC-based immunotherapy targeting functional cure in chronic hepatitis B, we found that upstream process optimization, rather than downstream purification, is the main driver of crude harvest quality and final drug product attributes. Iterative refinement of permissive cell growth cycles, time of harvest, and multiplicity of infection, guided by a robust, tiered analytical strategy, delivered high-purity harvests with superior infectivity ratios, reduced host cell residuals, minimized product-related impurities, and diminished downstream processing demands. These manufacturing refinements supported GMP production and Phase 1b clinical outcomes demonstrating safety, tolerability, and significant anti-HBV activity in chronically infected patients. We contend that the bioprocessing community's longstanding emphasis on downstream polishing overlooks the foundational role of upstream control in addressing AdC-specific hurdles. Reprioritizing upstream-first strategies holds transformative potential to improve vector quality, enhance safety profiles, accelerate development timelines, and increase cost-effectiveness for AdC and related vector platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.